NCT03962660 (HaRTS-TRENDS) is a NA clinical trial of HaRTS-TRENDS in Smoking, Tobacco, sponsored by University of Washington.

Who is sponsoring NCT03962660?

NCT03962660 is sponsored by University of Washington.

What drugs are being tested in NCT03962660?

Interventions in NCT03962660: HaRTS-TRENDS, Standard Care (SC).

What condition does NCT03962660 study?

NCT03962660 studies Smoking, Tobacco.

Is NCT03962660 still recruiting?

NCT03962660 is currently status unknown. Last updated 24 May 2019.

Last reviewed 2019-05-24 · How we verify

NCT03962660: HaRTS-TRENDS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Harm Reduction for Tobacco Smoking With Support of Tobacco-Replacing Electronic Nicotine Delivery Systems

Status unknown NA Last updated 24 May 2019

What this trial tests

NA trial testing HaRTS-TRENDS in Smoking, Tobacco in 94 participants. Status unknown.

Timeline

9 May 2019

Primary endpoint
30 April 2021

31 December 2021

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	94
Start date	9 May 2019
Primary completion	30 April 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

HaRTS-TRENDS
Standard Care (SC)

Conditions studied

Smoking, Tobacco — all drugs for Smoking, Tobacco →

Sponsor

University of Washington

Who can join

Adults 21 to 65, any sex, with Smoking, Tobacco. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the effectiveness of HaRTS-TRENDS compared to standard care (i.e., brief advice to quit + referral to state quit line that offers free NRT) in facilitating a biochemically verified nonsmoking and b) reducing smoking-related harm as measured by concentration of urinary tobacco-specific nitrosamines (TSNAs). Potential underlying mechanisms of changes in the proposed outcomes--including nicotine craving and smoking reduction, respectively--will be tested.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Electronic cigarettes for smoking cessation.
Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, et al · · 2020 · cited 314× · PMID 33052602 · DOI 10.1002/14651858.cd010216.pub4
Electronic cigarettes for smoking cessation.
Hartmann-Boyce J, Lindson N, Butler AR, McRobbie H, et al · · 2022 · cited 147× · PMID 36384212 · DOI 10.1002/14651858.cd010216.pub7
Electronic cigarettes for smoking cessation.
Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, et al · · 2021 · cited 126× · PMID 33913154 · DOI 10.1002/14651858.cd010216.pub5
Electronic cigarettes for smoking cessation.
Hartmann-Boyce J, McRobbie H, Butler AR, Lindson N, et al · · 2021 · cited 106× · PMID 34519354 · DOI 10.1002/14651858.cd010216.pub6
Electronic cigarettes for smoking cessation.
Lindson N, Butler AR, McRobbie H, Bullen C, et al · · 2024 · cited 94× · PMID 38189560 · DOI 10.1002/14651858.cd010216.pub8
Electronic cigarettes for smoking cessation.
Lindson N, Butler AR, McRobbie H, Bullen C, et al · · 2025 · cited 32× · PMID 39878158 · DOI 10.1002/14651858.cd010216.pub9

Verify or expand the search:

Other recruiting trials for Smoking, Tobacco

Currently open trials in the same condition.

NCT06945120 — ACT Lung Health Intervention: Phase Two · NA · recruiting
NCT06693700 — A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home · NA · recruiting
NCT06535867 — The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorde · recruiting
NCT05660525 — Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia · NA · recruiting
NCT05786547 — V+PSF-M for Tobacco Cessation in HIV Care in India · Phase 3 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03962660 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 24 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03962660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing